Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry and Commerce, aiming to leverage their respective advantageous resources to create a comprehensive medical service platform. The collaboration will provide a range of health services, including high-end medical care, cell health, early tumor screening, and cell therapy, as well as offering whole life cycle health solutions.
Expanding Health Services and Medical Platforms
The partnership seeks to enhance medical services by combining the expertise of Shanghai Cell Therapy Group with the network and resources of the Nantong Federation of Industry and Commerce. This collaboration will cover various aspects of healthcare, from advanced medical treatments to cell therapies, addressing the growing demand for comprehensive health solutions.
BZD1901: A Pioneering CAR-T Therapy for Mesothelin Positive Tumors
Shanghai Cell Therapy Group’s BZD1901 has been recognized as the world’s first autocrine nanoantibody CAR-T therapy for the treatment of mesothelin positive advanced solid tumors. Clinical results of this innovative therapy were presented at the ASCO 2022 annual meeting, highlighting its potential impact on cancer treatment. BZD1901 has received Investigational New Drug (IND) approval in China and orphan drug designation (ODD) in the US this year, marking a significant step forward in the development of novel cancer therapies.-Fineline Info & Tech
